JP7837274B2 - Ｋｌｋ５に対する抗体 - Google Patents

Ｋｌｋ５に対する抗体

Info

Publication number
JP7837274B2
JP7837274B2 JP2022547072A JP2022547072A JP7837274B2 JP 7837274 B2 JP7837274 B2 JP 7837274B2 JP 2022547072 A JP2022547072 A JP 2022547072A JP 2022547072 A JP2022547072 A JP 2022547072A JP 7837274 B2 JP7837274 B2 JP 7837274B2
Authority
JP
Japan
Prior art keywords
antibody
klk5
seq
cdr
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022547072A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512304A (ja
JP2023512304A5 (https=
Inventor
デディ、ネーシャ
チャールズ エリオット、ピーター
フランス ローマン レイセン、セッペ
メイソン、ショーン
ジェイムズ マクミラン、デイヴィッド
クレア ネス、ギリアン
ペンゴ、ニッコロ
アンソニー レッドヘッド、マーティン
ターナー、アリソン
ルイーズ タイソン、ケリー
Original Assignee
ユーシービー バイオファルマ エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーシービー バイオファルマ エスアールエル filed Critical ユーシービー バイオファルマ エスアールエル
Publication of JP2023512304A publication Critical patent/JP2023512304A/ja
Publication of JP2023512304A5 publication Critical patent/JP2023512304A5/ja
Application granted granted Critical
Publication of JP7837274B2 publication Critical patent/JP7837274B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2022547072A 2020-02-03 2021-02-01 Ｋｌｋ５に対する抗体 Active JP7837274B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2001447.8 2020-02-03
GBGB2001447.8A GB202001447D0 (en) 2020-02-03 2020-02-03 Antibodies
GB2008022.2 2020-05-28
GBGB2008022.2A GB202008022D0 (en) 2020-02-03 2020-05-28 Antibodies
PCT/EP2021/052249 WO2021156171A1 (en) 2020-02-03 2021-02-01 Antibodies against klk5

Publications (3)

Publication Number Publication Date
JP2023512304A JP2023512304A (ja) 2023-03-24
JP2023512304A5 JP2023512304A5 (https=) 2025-05-16
JP7837274B2 true JP7837274B2 (ja) 2026-03-30

Family

ID=69800047

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022547072A Active JP7837274B2 (ja) 2020-02-03 2021-02-01 Ｋｌｋ５に対する抗体
JP2022547167A Active JP7839093B2 (ja) 2020-02-03 2021-02-01 Ｋｌｋ５に対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022547167A Active JP7839093B2 (ja) 2020-02-03 2021-02-01 Ｋｌｋ５に対する抗体

Country Status (20)

Country Link
US (2) US20230070261A1 (https=)
EP (2) EP4100442A1 (https=)
JP (2) JP7837274B2 (https=)
KR (2) KR20220137669A (https=)
CN (2) CN115038722A (https=)
AR (2) AR121255A1 (https=)
AU (2) AU2021217523A1 (https=)
BR (2) BR112022015281A2 (https=)
CA (2) CA3169838A1 (https=)
CL (2) CL2022002079A1 (https=)
CO (2) CO2022012062A2 (https=)
EC (2) ECSP22060844A (https=)
GB (2) GB202001447D0 (https=)
IL (2) IL295247A (https=)
MX (2) MX2022009474A (https=)
PE (2) PE20221921A1 (https=)
PH (2) PH12022551962A1 (https=)
TW (2) TWI861354B (https=)
WO (2) WO2021156171A1 (https=)
ZA (2) ZA202208589B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022192647A1 (en) * 2021-03-12 2022-09-15 Genentech, Inc. Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178316A1 (en) 2018-03-14 2019-09-19 Genentech, Inc. Anti-klk5 antibodies and methods of use

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8927230D0 (en) * 1989-12-01 1990-01-31 Unilever Plc Reagents
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
PT1049787E (pt) 1998-01-23 2005-04-29 Vlaams Interuniv Inst Biotech Derivados de anticorpos multipropositos
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
WO2004041863A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
ES2374068T3 (es) 2002-12-03 2012-02-13 Ucb Pharma, S.A. Ensayo para identificar células productoras de anticuerpos.
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ612578A (en) * 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
WO2013068571A1 (en) 2011-11-11 2013-05-16 Ucb Pharma S.A. Albumin binding antibodies and binding fragments thereof
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
SI3097085T1 (sl) * 2014-01-23 2020-11-30 Sixera Pharma Ab Derivati benzoksazinona za zdravljenje kožnih bolezni
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201411420D0 (en) 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
CN108112254B (zh) * 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
EP3624820A1 (en) * 2017-04-21 2020-03-25 H. Hoffnabb-La Roche Ag Use of klk5 antagonists for treatment of a disease
GB201811368D0 (en) 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178316A1 (en) 2018-03-14 2019-09-19 Genentech, Inc. Anti-klk5 antibodies and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J.Mol. Biol.，2007年，373，pp.1017-1031
PLOS GENETICS，2015年，11(9)，e1005389

Also Published As

Publication number Publication date
PH12022551963A1 (en) 2023-10-09
EP4100442A1 (en) 2022-12-14
CO2022012062A2 (es) 2022-08-30
BR112022015281A2 (pt) 2022-09-20
IL295248A (en) 2022-10-01
CA3169838A1 (en) 2021-08-12
PE20221921A1 (es) 2022-12-29
US20230075753A1 (en) 2023-03-09
CN115052900A (zh) 2022-09-13
ZA202208589B (en) 2023-12-20
JP2023512304A (ja) 2023-03-24
US20230070261A1 (en) 2023-03-09
WO2021156170A1 (en) 2021-08-12
KR20220137669A (ko) 2022-10-12
AR121254A1 (es) 2022-05-04
ECSP22060844A (es) 2022-12-30
CA3169842A1 (en) 2021-08-12
TWI861354B (zh) 2024-11-11
CL2022002079A1 (es) 2023-01-06
PE20221922A1 (es) 2022-12-29
MX2022009474A (es) 2022-08-22
CO2022012061A2 (es) 2022-08-30
BR112022015279A2 (pt) 2022-09-20
IL295247A (en) 2022-10-01
WO2021156171A1 (en) 2021-08-12
ZA202208588B (en) 2023-12-20
AU2021217523A1 (en) 2022-09-01
TW202134276A (zh) 2021-09-16
MX2022009475A (es) 2022-08-22
ECSP22060834A (es) 2022-09-30
CN115038722A (zh) 2022-09-09
KR20220137668A (ko) 2022-10-12
CL2022002078A1 (es) 2023-01-06
GB202008022D0 (en) 2020-07-15
GB202001447D0 (en) 2020-03-18
JP7839093B2 (ja) 2026-04-01
EP4100441A1 (en) 2022-12-14
JP2023512320A (ja) 2023-03-24
TW202140569A (zh) 2021-11-01
PH12022551962A1 (en) 2023-10-09
AR121255A1 (es) 2022-05-04
AU2021216646A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
US12410244B2 (en) Anti-alpha-synuclein antibodies
US12545720B2 (en) Anti-alpha-synuclein antibodies
JP7837274B2 (ja) Ｋｌｋ５に対する抗体
RU2847361C1 (ru) Антитела против klk5
EA041378B1 (ru) Антитела к альфа-синуклеину

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250507

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260227

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260317

R150 Certificate of patent or registration of utility model

Ref document number: 7837274

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150